A5008376174- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Diversity and Career in Medicine
- Molecular Biology Techniques and Applications
- Renal and related cancers
- Cancer, Lipids, and Metabolism
- Urologic and reproductive health conditions
- Global Health Workforce Issues
- Genital Health and Disease
- Urinary Tract Infections Management
- Healthcare Policy and Management
- Medical Education and Admissions
- Viral-associated cancers and disorders
- Pediatric Urology and Nephrology Studies
- Epigenetics and DNA Methylation
- Colorectal Cancer Screening and Detection
- Global Cancer Incidence and Screening
- Ureteral procedures and complications
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Statistical Methods in Clinical Trials
University of Virginia
2022-2024
Urology of Virginia
2024
University of Virginia Health System
2023
Jones Institute
2022
HollyFrontier (United States)
2022
University of Wisconsin–Madison
2012-2021
University of Wisconsin Carbone Cancer Center
2013-2020
Akron General Medical Center
2020
Cleveland Clinic
2020
Madison Group (United States)
2012-2019
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on clinical presentation and workup of suspected bladder cancer, treatment non–muscle-invasive urothelial metastatic cancer because important updates have recently been made to these sections. Some include recommendations optimal event a bacillus Calmette-Guérin (BCG) shortage details about biomarker testing advanced or disease. The systemic therapy second-line subsequent...
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy muscle-invasive urothelial bladder cancer, as substantial revisions were made 2017 updates, such new recommendations nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of addresses additional aspects management including non-muscle-invasive cancer nonurothelial histologies, well staging, evaluation, follow-up.
The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These Insights discuss important updates to 2018 version guidelines, including implications 8th edition AJCC Staging Manual on treatment muscle-invasive cancer incorporating newly approved immune checkpoint inhibitor therapies into options locally advanced or metastatic disease.
Open AccessJournal of UrologyAdult Urology5 May 2024Efficacy Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non–muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial Vikram M. Narayan, Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, Joseph E. Busby, Michael Poch, Paul L. Crispen, Gary Steinberg, Anne K. Schuckman, Tracy Downs,...
We used a population based cancer registry to examine trends in renal cell carcinoma incidence and survival among 4 racial/ethnic groups (white, black, Hispanic Asian/Pacific Islander) both genders.
Purpose Many patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa Syn3 (rAd-IFNα/Syn3), a replication-deficient gene transfer vector, for high-grade (HG) BCG-refractory relapsed NMIBC. Methods In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials.gov identifier:...
Patients presenting with microhematuria represent a heterogeneous population broad spectrum of risk for genitourinary malignancy. Recognizing that patient-specific characteristics modify the underlying malignant etiologies, this guideline sought to provide personalized diagnostic testing strategy.The systematic review incorporated evidence published from January 2010 through February 2019, an updated literature search include studies up December 2019. Evidence-based statements were developed...
No AccessJournal of UrologyAdult Urology1 May 2018Efficacy and Safety Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance Bladder Cancer: A Phase III, Comparative, Multicenter Studyis corrected byERRATUM Siamak Daneshmand, Sanjay Patel, Yair Lotan, Kamal Pohar, Edouard Trabulsi, Michael Woods, Tracy Downs, William Huang, Jeffrey Jones, O’Donnell, Trinity Bivalacqua, Joel DeCastro, Gary Steinberg, Ashish Kamat, Matthew Resnick, Badrinath Konety, Mark Schoenberg, J....
To investigate efficacy of neoadjuvant tyrosine kinase-inhibitor therapy (TKI) before imperative nephron-sparing surgery (NSS), as NSS in patients with large locally advanced or centrally located tumours can be challenging, and TKI might result a reduction primary tumour burden increase the feasibility NSS.This was multicentre retrospective review prospective pilot study undergoing sunitinib planned from February 2006 to 2009. All underwent confirmatory biopsy for clear cell renal carcinoma....
BACKGROUND Many patients with low‐risk prostate cancer (PC) who are diagnosed Gleason score 6 at biopsy ultimately found to harbor higher grade PC (Gleason ≥ 7) radical prostatectomy. This finding increases risk of recurrence and cancer‐specific mortality. Validated clinical tools that available preoperatively needed improve the ability recognize likelihood upgrading in PC. METHODS More than 30 clinicopathologic parameters were assessed consecutive upon underwent A nomogram for predicting on...
Abstract We performed a phase II pharmacodynamic prevention trial of Polyphenon E [a green tea polyphenol formulation primarily consisting epigallocatechin gallate (EGCG)] in patients prior to bladder cancer surgery. Patients with tumor were randomized receive containing either 800 or 1,200 mg EGCG placebo for 14 28 days transurethral resection cystectomy. The primary objective was compare the postintervention tissue levels receiving as compared placebo. Secondary objectives included...
Abstract Background Prostate cancer is one of the leading causes illness and death among men in United States world wide. There an urgent need to discover good biomarkers for early clinical diagnosis treatment. Previously, we developed exon-junction microarray-based assay profiled 1532 mRNA splice isoforms from 364 potential prostate related genes 38 tissues. Here, investigate advantage using isoforms, which couple transcriptional splicing regulation, classification. Results As many as 464...
We examined the incidence rates of bladder cancer using California Cancer Registry data to determine if any trends exist.Complete records 55,159 cases invasive were from original 92,677 recorded in between 1988 and 2004.California showed a universal late age peak specific men women, across ethnic boundaries. The rate annual increase percent individuals 85 years or older was increasing about 10 times as rapidly population that (slope = 0.395 vs 0.0336). Furthermore, during all 17 proportion...
Metformin is commonly prescribed for patients with type 2 diabetes mellitus. We hypothesized that metformin plus androgen deprivation therapy may be beneficial in combination. Our objective was to assess this combination a retrospective cohort of advanced prostate cancer.Using national Veterans Affairs databases we identified all men diagnosed cancer between 2000 and 2008 who were treated followup through May 2016. Study exclusions included treatment 6 months or longer, receipt concurrently...